Definitive Contract HR001117C0092
Award Date
9/15/17
Potential Completion Date
2/10/22
Potential Value
$10M
Federal Agency
Defense Advanced Research Projects Agency
Awardee
Ginkgo Bioworks, Inc.
Ultimate Awardee
Not listed
NAICS Category
541712 - Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Cost Plus Fixed Fee
Place of Performance
Boston, MA 02210, USA
Solicitation Procedures
Basic Research
Number Of Offers Received
23
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a $4,797,261 definitive contract awarded by the Defense Advanced Research Projects Agency (DARPA) to Ginkgo Bioworks, Inc., a biotechnology company based in Boston. The contract is for DARPA's "SUPERB: SYNBIO + UNIVERSAL PURIFICATION OF EXTRACT-DERIVED, RIGHT-ON-TIME BIOLOGICS" program, which aims to develop technologies enabling immediate synthesis of bioactive protein medical countermeasures and production enzymes within 24 hours at a yield of at least 500 doses per week....
This is a Cost Plus Fixed Fee contract awarded by the Navy NAVSUP Engineering Logistics Office to Ginkgo Bioworks, Inc., a Boston-based biotechnology company, for the IARPA FELIX PROGRAM. The contract has a ceiling value of $5,338,550.00 and a completion date of June 30, 2022. Ginkgo Bioworks is a for-profit manufacturer of goods that specializes in cellular engineering, DNA sequencing, and advanced biological manufacturing services. The company has a proven track record of delivering complex...
This is a $3,999,210.00 cost-plus-fixed-fee definitive contract awarded by the Department of the Navy Information Warfare Systems Command to Ginkgo Bioworks, Inc., a biotechnology firm based in Boston, for the DNA Recording Intrinsic Cellular Biointelligence (DRINC BIO) project. The contract has a completion date of May 21, 2025 and was awarded on May 2, 2023 with no set-aside designation. Ginkgo Bioworks provides research, testing, and production services related to cellular engineering, DNA...
This $50,216,772.13 Firm Fixed Price Delivery Order contract was awarded to Ginkgo Bioworks, Inc., a biotechnology company based in Boston, Massachusetts. The contract is for test surge and data sharing services under a larger Indefinite Delivery/Indefinite Quantity (IDIQ) vehicle held with the Centers for Disease Control and Prevention (CDC). The IDIQ has a total ceiling value of $118 million and an ultimate completion date of September 5, 2029. Ginkgo Bioworks has previously provided...
This is a $12,045,252.00 cost-plus-fixed-fee contract awarded by the Defense Advanced Research Projects Agency (DARPA) to Ginkgo Bioworks, Inc., a Boston-based biotechnology company. The contract is for the "ICE CONTROL FOR COLD ENVIRONMENTS (ICE)" program, which seeks to develop biologically-sourced or inspired molecules to inhibit ice crystallization, propagation, and adhesion to mitigate extreme cold weather challenges for Department of Defense (DoD) applications. The original...
This is a $14,605,403.00 cost-plus-fixed-fee definitive contract awarded by the Defense Advanced Research Projects Agency (DARPA) to Ginkgo Bioworks, Inc., a Boston-based biotechnology company. The contract is part of DARPA's ReVector program, which aims to develop methods to use human skin microbiomes to modulate chemical production in order to avoid mosquito attraction and feeding, thereby reducing the threat of mosquito-borne disease to U.S. military personnel. The original solicitation, with...
The U.S. Centers for Disease Control and Prevention (CDC) awarded a $85,741,227.24 Firm Fixed Price Definitive Contract to Ginkgo Bioworks, Inc., a biotechnology company in Boston, Massachusetts, for a Traveler-Based Genomic Surveillance Program. The contract has an ultimate completion date of March 21, 2028 and was not set aside for a specific business category. This contract appears to build on Ginkgo Bioworks' previous work with the CDC on COVID-19 genomic testing and surveillance at major...
This is a $1,205,149.24 Firm Fixed Price contract awarded by the Centers for Disease Control and Prevention (CDC) to Ginkgo Bioworks, Inc., a biotechnology company based in Boston, Massachusetts. The contract, titled "TRAVELER-BASED GENOMIC SURVEILLANCE," is for the provision of biotechnology services to support the CDC's public health monitoring and emergency response initiatives. The contract has an ultimate completion date of September 19, 2024 and was awarded on August 26, 2024....
The National Institutes of Health's National Heart, Lung and Blood Institute awarded Ginkgo Bioworks, Inc. a $6.57 million firm fixed price definitive contract to support the Rapid Acceleration of Diagnostics-Advanced Technology Platforms program. The goal of this program is to increase SARS-CoV-2 testing capacity and throughput by identifying existing testing platforms that can be used for COVID-19 diagnostics. Work will be performed by Ginkgo Bioworks in Boston, Massachusetts over a one year...
The Centers for Disease Control and Prevention (CDC) awarded a $76,575,638.04 firm-fixed-price contract to Ginkgo Bioworks, Inc., a Boston-based biotechnology company, to conduct genomic testing and surveillance of SARS-CoV-2 at five major U.S. international airports. The contract, which runs through March 21, 2025, requires Ginkgo Bioworks to collect a minimum of 483,000 biological samples per year from international travelers and perform on-site reverse transcription polymerase chain...